Apr 05, 2017
Nordic Pharma has declared the dispatch of Nordimet®, another methotrexate pre-filled auto-injector PEN for the treatment of different auto-immune conditions including active juvenile idiopathic arthritis (JIA), rheumatoid arthritis (RA), polyarthritic types of severe, extreme headstrong debilitating psoriasis and extreme psoriatic arthritis.
Nordimet® is the first button-free, once-a-weekly PEN gadget containing the active substance methotrexate; the most usually utilized Disease Modifying Anti-Rheumatic Drug (DMARD) for the treatment of rheumatoid arthritis (RA).
General manager Tony Bratt from Nordic Pharmaceuticals, UK said “Very often bringing new medicines to the market is not about re-inventing the wheel, but optimising something in existence. Taking an established treatment like methotrexate for instance and providing it in a device to help improve patients’ experience with treatment.”
In a survey of 149 medical nurses, 87% detailed that the PEN gadget was simple and easily accessible, with the majority of them around 86% expressing that their patients will have an user-friendly experience in contrast to a button-activated gadget. In a different bit of research, when patients with rheumatoid arthritis (RA) were asked which instrument they favored, all around 100% expressed that they favored the new, methotrexate button-free gadget and thought that it is simpler to use in comparison with the already existing gadgets.
Apr 11, 2017
All Copyrights reserve worldhealthcarenews.biz 2017.